These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

909 related articles for article (PubMed ID: 30850561)

  • 1. Direct Costs Associated with Relapsed Diffuse Large B-Cell Lymphoma Therapies.
    Purdum A; Tieu R; Reddy SR; Broder MS
    Oncologist; 2019 Sep; 24(9):1229-1236. PubMed ID: 30850561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of the addition of rituximab to CHOP in young patients with good-prognosis diffuse large-B-cell lymphoma.
    Ferrara F; Ravasio R
    Clin Drug Investig; 2008; 28(1):55-65. PubMed ID: 18081361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nationwide claims database analysis of treatment patterns, costs and survival of Japanese patients with diffuse large B-cell lymphoma.
    Tsutsué S; Tobinai K; Yi J; Crawford B
    PLoS One; 2020; 15(8):e0237509. PubMed ID: 32810157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world total cost of care by line of therapy in relapsed/refractory diffuse large B-cell lymphoma.
    Gatwood J; Masaquel A; Fox D; Sheinson D; James C; Li J; Hossain F; Ross R
    J Med Econ; 2024; 27(1):738-745. PubMed ID: 38686393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab (MabThera) for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation.
    Knight C; Hind D; Brewer N; Abbott V
    Health Technol Assess; 2004 Sep; 8(37):iii, ix-xi, 1-82. PubMed ID: 15361313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Characteristics, Treatment Patterns, Health Care Resource Use, and Costs of Patients with Diffuse Large B-Cell Lymphoma in the U.S.
    Yang X; Laliberté F; Germain G; Raut M; Duh MS; Sen SS; Lejeune D; Desai K; Armand P
    Oncologist; 2021 May; 26(5):e817-e826. PubMed ID: 33616256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world costing analysis for diffuse large B-cell lymphoma in British Columbia.
    Costa S; Scott DW; Steidl C; Peacock SJ; Regier DA
    Curr Oncol; 2019 Apr; 26(2):108-113. PubMed ID: 31043812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of best supportive care, CHOP, or R-CHOP for treatment of diffuse large B-cell lymphoma in Malawi: a cost-effectiveness analysis.
    Painschab MS; Kohler R; Kimani S; Mhango W; Kaimila B; Zuze T; Mithi V; Kasonkanji E; Mumba N; Nyasosela R; Wheeler S; Gopal S
    Lancet Glob Health; 2021 Sep; 9(9):e1305-e1313. PubMed ID: 34303416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of the addition of rituximab to CHOP chemotherapy in first-line treatment for diffuse large B-cell lymphoma in a population-based observational cohort in British Columbia, Canada.
    Johnston KM; Marra CA; Connors JM; Najafzadeh M; Sehn L; Peacock SJ
    Value Health; 2010; 13(6):703-11. PubMed ID: 20561333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Costs associated with diffuse large B-cell lymphoma patient treatment in a Canadian integrated cancer care center.
    Lee RC; Zou D; Demetrick DJ; Difrancesco LM; Fassbender K; Stewart D
    Value Health; 2008; 11(2):221-30. PubMed ID: 18380634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma.
    Hornberger JC; Best JH
    Cancer; 2005 Apr; 103(8):1644-51. PubMed ID: 15756658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain.
    Sabater E; López-Guillermo A; Rueda A; Salar A; Oyagüez I; Collar JM
    Appl Health Econ Health Policy; 2016 Aug; 14(4):465-477. PubMed ID: 27090915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment patterns and costs among US patients with diffuse large B-cell lymphoma not treated with 2L stem cell transplantation.
    Acheampong T; Gu T; Le TK; Keating SJ
    Future Oncol; 2024 Mar; 20(10):623-634. PubMed ID: 38230990
    [No Abstract]   [Full Text] [Related]  

  • 14. Real-world patient characteristics, treatment patterns, and treatment outcomes of patients with diffuse large B-cell lymphoma by line of therapy.
    Sineshaw HM; Zettler CM; Prescott J; Garg M; Chakraborty S; Sarpong EM; Bai C; Belli AJ; Fernandes LL; Wang CK
    Cancer Med; 2024 Apr; 13(7):e7173. PubMed ID: 38597118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of Prognosis for Patients with Diffuse Large B-Cell Lymphoma Refractory to or in First Relapse After Initial R-CHOP Therapy: A Single-Institution Study.
    Yamamoto M; Watanabe K; Fukuda T; Miura O
    Anticancer Res; 2017 May; 37(5):2655-2662. PubMed ID: 28476841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of rituximab combined with chop for treatment of diffuse large B-cell lymphoma.
    Best JH; Hornberger J; Proctor SJ; Omnes LF; Jost F
    Value Health; 2005; 8(4):462-70. PubMed ID: 16091023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extranodal site of diffuse large B-cell lymphoma and the risk of R-CHOP chemotherapy resistance and early relapse.
    Ting CY; Gan GG; Bee-Lan Ong D; Tan SY; Bee PC
    Int J Clin Pract; 2020 Oct; 74(10):e13594. PubMed ID: 32583545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed/ Refractory Diffuse Large B Cell Lymphoma.
    Xiao Z; Li J; Miao K
    Curr Stem Cell Res Ther; 2017; 12(1):14-18. PubMed ID: 27396370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of frontline autologous stem cell transplantation in young, high-risk diffuse large B-cell lymphoma patients.
    Yoon JH; Kim JW; Jeon YW; Lee SE; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Lee JW; Min WS; Park CW; Cho SG
    Korean J Intern Med; 2015 May; 30(3):362-71. PubMed ID: 25995667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-World Survival, Healthcare Resource Utilization, and Costs Among U.S. Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Treated With R-GemOx in the Relapsed/Refractory Setting.
    Garg M; Puckett J; Kamal-Bahl S; Raut M; Ryland KE; Doshi JA; Huntington SF
    Clin Lymphoma Myeloma Leuk; 2024 May; 24(5):e181-e190. PubMed ID: 38433043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.